Septerna, Inc. (NASDAQ:SEPN) Given Average Rating of “Moderate Buy” by Analysts

Shares of Septerna, Inc. (NASDAQ:SEPN) have earned an average rating of “Moderate Buy” from the ten ratings firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $43.1250.

Several analysts have issued reports on SEPN shares. HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Septerna in a research report on Wednesday, May 13th. Truist Financial increased their target price on shares of Septerna from $34.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, March 11th. JPMorgan Chase & Co. increased their target price on shares of Septerna from $34.00 to $38.00 and gave the stock an “overweight” rating in a report on Tuesday, March 24th. Cantor Fitzgerald restated an “overweight” rating and issued a $60.00 price objective on shares of Septerna in a report on Tuesday, March 10th. Finally, Wall Street Zen lowered shares of Septerna from a “buy” rating to a “hold” rating in a report on Saturday, March 14th.

Septerna Stock Up 5.7%

NASDAQ SEPN opened at $28.01 on Thursday. The company has a 50-day simple moving average of $24.96 and a two-hundred day simple moving average of $25.65. Septerna has a 12-month low of $8.86 and a 12-month high of $32.63. The firm has a market cap of $1.26 billion, a price-to-earnings ratio of -34.58 and a beta of 2.21.

Septerna (NASDAQ:SEPN) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.23. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. The business had revenue of $26.52 million during the quarter, compared to analyst estimates of $16.98 million. Equities analysts expect that Septerna will post -1.61 earnings per share for the current fiscal year.

Insider Activity

In other Septerna news, insider Samira Shaikhly sold 70,453 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $28.10, for a total value of $1,979,729.30. Following the completion of the sale, the insider directly owned 793 shares in the company, valued at $22,283.30. This trade represents a 98.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, COO Elizabeth Bhatt sold 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $24.34, for a total transaction of $97,360.00. Following the transaction, the chief operating officer directly owned 174,209 shares of the company’s stock, valued at $4,240,247.06. This represents a 2.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Septerna

Institutional investors and hedge funds have recently made changes to their positions in the business. Group One Trading LLC increased its stake in shares of Septerna by 111.8% during the fourth quarter. Group One Trading LLC now owns 944 shares of the company’s stock valued at $26,000 after purchasing an additional 8,955 shares in the last quarter. Global Retirement Partners LLC bought a new stake in shares of Septerna during the fourth quarter valued at approximately $35,000. Russell Investments Group Ltd. bought a new stake in shares of Septerna during the third quarter valued at approximately $36,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Septerna during the fourth quarter valued at approximately $53,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Septerna during the fourth quarter valued at approximately $61,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.